Fortress Biotech Announces Provisional Patent Application for CAEL-101

Fortress Biotech (NASDAQ:FBIO) announced a provisional patent application in the US from Columbia University relating to CAEL-101.
As quoted in the press release:

CAEL-101, which was licensed from Columbia to Fortress subsidiary Caelum Biosciences (“Caelum”) in January 2017.

The patent application, once converted into a U.S. non-provisional, utility application, will provide composition of matter protection for CAEL-101, effective upon a grant of a U.S. patent.  The legal protection offered by a granted U.S. patent will exceed any data exclusivity periods associated with Orphan Drug Designation and/or an original, branded biologic product approved for marketing in the U.S.  Caelum also plans to pursue an international (PCT) application, from which national stage patent applications can be submitted in both industrial jurisdictions and developing countries around the world.

Click here to read the full press release.

Source: globenewswire.com